Beijing Hotgen Biotech Co., Ltd.
Location
Beijing
Founded
2005-10-23
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., In Vitro and In Vivo Diagnostic Substances), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Beijing Hotgen Biotech Co., Ltd.
Live alerts from global media, monitored by Business Radar
2025-03-22 (yicaiglobal.com)
Net profit plummeted but the stock price rose sharply, and Tongcheng Hotjing, a shareholder of Hotgen Biotech, planned to reduce its holdings of no more than 2% of its shares
On the evening of March 21, Hotgen Biotechnology (688068) announced that the company recently received the "Notification Letter on Reducing the Company's Shares" issued by shareholder Tongcheng Hotjing. Due to its own capital needs, shareholder Tongcheng Hotjing plans to reduce its holdings of the company's shares by centralized bidding and block trading to no more than 1.8 million shares, accounting for 1.9465% of the company's total share capital.
Read more
2025-03-08 (cnfol.com)
Rejing Bio (688068.SH): Bioinnovative drugs and tumor early screening and other related businesses are independently operated by associates_Individual Stock Information_Market_CICC Online
Zhitong Finance APP News Rejing Bio 688068 SH issued an announcement on stock price abnormality, saying that the company's current main business is R&D, production and sales of in vitro diagnostic reagents and supporting instruments, and related businesses such as innovative drugs and tumor screening are independently operated by the company's associate companies Shunjing Pharmaceutical Yaojing Gene Zhiyuan Bio and Aoru Bio. The related businesses have large R&D investment and R&D style.
Read more
2024-11-22 (businessupturn.com)
Stock Market news : Wuhan Golden Laser Leads Gainers with 20.03% Rise; Beijing Hotgen Biotech Drops 9.59%
Wuhan Golden Laser surged 20.03% to 14.92 CNY, topping the gainers, while Beijing Hotgen Biotech led losses, declining 9.59% to 45.84 CNY amid mixed market performance.
Read more
2022-03-15 (sogou.com)
Antigen self-testing product sales pre-orders surge online
and Beijing Hotgen Biotech.As of press time, the Beijing Hotgen test kits sold on the platform by Jinxiang Pharmacy had run out. Pre-...
Read more
2021-03-08 (sogou.com)
Germany's new crown self-test reagents were sold out, and overseas antigen reagents were welcomed again!
(Beijing Hotgen Biotech Co., Ltd) In addition, many Chinese manufacturers have also successfully developed antigen detection reagents for the new crown, such as: (The examples here are incomplete, welcome to add them) ...
Read more
(openpr.com)
First in the world Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency use antibody drug for AMI
Press release - Getnews - First in the world Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency use antibody drug for AMI - published on openPR.com
Read more
(cls.cn)
Rejing Bio acquired the equity of Aorui Bio at a premium of more than 13 times. The cancer early screening track is still in the commercial exploration stage.
According to the Financial Associated Press (Beijing, reporters: Xu Haidong and Liang Wei), Rejing Bio (688068) announced today that it plans to acquire a 38.1% stake in Aorui Bio at a premium of 13 times to enter the early cancer screening business. In an interview with the Financial Associated Press, people in the medical industry pointed out that early cancer screening is still in the exploratory stage of profit model in terms of commercialization, and whether it can reach enough seed users is regarded as the lifeline of early cancer screening companies. From this perspective, Aorui Biotech is hardly ahead in terms of revenue, profitability, medical device qualification application process, etc., but the announcement stated that the company has two liver cancer diagnostic products
Read more